Skip to main content
. 2022 Oct 14;13:1011669. doi: 10.3389/fendo.2022.1011669

Figure 3.

Figure 3

Canagliflozin alleviates high glucose injury of cardiomyocytes by non-hypoglycemic way. (A) Effects of high concentration of glucose and different concentrations of canagliflozin on the cell viability of H9C2 cells. (B) Content of glucose in H9C2 cells of each group. (***: P<0.001; compared with CON group; #: P< 0.05; ##: P<0.01; ###: P<0.001; compared with HG group; n.s.: no significance.).